GLUE — Monte Rosa Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-06-24.
Performance
Technicals
Others in Healthcare
Measured signals that fired on GLUE
| date | signal | measured base rate |
|---|---|---|
| 2026-08-18 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-08-03 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-08-03 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-07-31 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-31 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-07-31 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-16 | Warmuth Markus President & CEO | Open-market sale | 9.5K | 23.18 | 220.2K |
| 2026-07-15 | Champoux Jennifer Chief Operating Officer | Open-market sale 10b5-1 plan | 4.4K | 23.38 | 101.7K |
| 2026-07-15 | Champoux Jennifer Chief Operating Officer | Option exercise 10b5-1 plan | 4.4K | 3.98 | 17.3K |
| 2026-07-06 | Townson Sharon Chief Scientific Officer | Open-market sale 10b5-1 plan | 5.6K | 23.25 | 130.2K |
| 2026-07-06 | Townson Sharon Chief Scientific Officer | Option exercise 10b5-1 plan | 6.0K | 6.14 | 36.8K |
| 2026-07-06 | Townson Sharon Chief Scientific Officer | Open-market sale 10b5-1 plan | 400 | 24.13 | 9.7K |
| 2026-07-01 | Behbahani Ali Director | Other Acquisition/Disposition | 15.0K | 0.00 | 0 |
| 2026-07-01 | Behbahani Ali Director | Other Acquisition/Disposition | 15.0K | 0.00 | 0 |
| 2026-07-01 | Behbahani Ali Director | Other Acquisition/Disposition | 1.0M | 0.00 | 0 |
| 2026-06-30 | Janku Filip Chief Medical Officer | Open-market sale 10b5-1 plan | 5.4K | 24.50 | 132.5K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| NEA Management Company, LLC | 126.5M | 7.7M |
| BlackRock, Inc. | 92.7M | 5.6M |
| TCG Crossover Management, LLC | 76.0M | 4.6M |
| BVF INC/IL | 73.4M | 4.5M |
| BAKER BROS. ADVISORS LP | 71.5M | 4.3M |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 69.5M | 4.2M |
| Vestal Point Capital, LP | 59.3M | 3.6M |
| STATE STREET CORP | 55.2M | 3.4M |
| BRAIDWELL LP | 52.7M | 3.2M |
| Versant Venture Management, LLC | 52.3M | 3.2M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-14 | — | on EDGAR ↗ |
| 10-Q | 2026-08-06 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-06 | 2026-08-06 | on EDGAR ↗ |
| 4 | 2026-07-17 | 2026-07-16 | on EDGAR ↗ |
| 4 | 2026-07-16 | 2026-07-15 | on EDGAR ↗ |
| 144 | 2026-07-16 | — | on EDGAR ↗ |
| 144 | 2026-07-15 | — | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about GLUE
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →